share_log

科伦药业:关于子公司核心产品芦康沙妥珠单抗(sac-TMT)的新药申请获国家药品监督管理局受理的公告

Colon Pharmaceutical: Announcement on the acceptance by the State Drug Administration of the new drug application for the subsidiary\'s core product, lukansastuzumab (Sac-TMT)

SZSI ·  Oct 31
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more